Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease

Abstract

Infection with herpes simplex viruses is one of the most ancient diseases described to affect humans. Infection with these viruses produces vexing effects to the host, which frequently recur. Infection with herpes simplex viruses is lifelong, and currently there is no vaccine or drug to prevent or cure infection. Prevalence of herpes simplex virus 2 (HSV-2) infection varies significantly depending on the geographical region and nears 20 % worldwide. Importantly, HSV-2 is the first cause of genital ulcers in the planet. HSV-2 affects approximately 500 million people around the globe and significantly increases the likelihood of acquiring the human immunodeficiency virus (HIV), as well as its shedding. Thus, controlling HSV-2 infection and spread is of public health concern. Here, we review the diseases produced by herpes simplex viruses, the factors that modulate HSV-2 infection, the relationship between HSV-2 and HIV and novel therapeutic and prophylactic microbicides/antivirals under development to prevent infection and pathological outcomes produced by this virus. We also review mutations associated with HSV-2 resistance to common antivirals.

Introduction

Humans and herpes simplex viruses (HSV) have interacted with each other for tens of thousands of years, as recently evidenced by phylogenetic analyses that relate HSV serotypes to the intercontinental migration of our ancestors [1]. Noteworthy, allusions to the diseases produced by these viruses date back to 2,000 years BC and the word herpes to ~400 BC by Hippocrates, who referred to the pathological outcomes produced by these viruses with the term herpein (to crawl in Greek), likely because of the pain that crawled through the skin of those affected [2, 3]. However, in the following centuries, the term herpes became widely used to describe skin lesions produced by numerous agents and conditions that not necessarily related to HSV. A more detailed description of the effects produced by HSV came hundreds of years later with the publication of De Morbis Venereis by John Astruc in 1736 that narrated with detail the pathological manifestations of herpes genitalis [4]. Later studies would describe the recurrent character of the disease, suggesting persistent infection [5, 6]. However, regardless of the early perception that herpetic diseases were transmissible from person to person, the infectious character of these pathologies only became evident at the end of the ninth century and beginning of the twentieth century. Experimental work performed by J. Vidal in humans [7] and Gruter in rabbits [8] demonstrated for the first time that herpes could be transmitted between individuals with material obtained from herpetic vesicles. Although these findings warned people about the infectivity of this disease, its threat has been somewhat underestimated since then with lesions commonly being described as “cold sores” and “fever blisters” in the oral area. Regretfully, these popular terms undervalue the persistent nature of HSV. Currently, the term herpes has found again common use to appropriately indicate disease produced by two closely related, but different viruses: herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2). Both HSV-1 and HSV-2 produce similar lesions that recur with variable frequency in skin and mucosae throughout the individual’s life and latently infect neurons of the trigeminal or dorsal root ganglia [9]. These neurotropic characteristics of HSV and their capacity to escape the host immune response make these viruses successful pathogens, as evidenced by their capacity to persist within individuals and remain at a high prevalence in the population [10].

Clinical manifestations of HSV-2

Infection with HSV-1 or HSV-2 generally requires intimate contact with an infected individual (e.g., sexual intercourse and saliva exchange). However, direct contact of infected tissues with mucosae (e.g., eyes, genitalia) or eroded skin (e.g., with abrasions, microlesions) also provides entry portals for HSV in the host [11]. Although herpetic lesions in the oro-facial area are commonly attributed to HSV-1 and herpetic lesions in the genital area are associated with HSV-2, infections at both sites can occur with these two viruses [12, 13].

Common pathologies produced by HSV include gingivostomatitis, herpes labialis and herpes genitalis, which are generally characterized by vesicular ulcers, although these may be less evident in the genital area [13–16]. Herpetic lesions contain high amounts of virions and infiltrating leukocytes that combat infection and last 2–21 days followed by the establishment of scabs that are resolved without scarification. HSV-1 and HSV-2 can also result in multiple other skin diseases, such as eczema herpeticum in individuals with atopic dermatitis that can be life-threatening for infants [17, 18], herpetic whitlow, which manifests as lesions at the finger tips [19, 20] and herpes gladiatorum [11, 21], an herpetic condition facilitated by eroded skin and frequently observed in individuals that practice contact sports such as wrestling (Fig. 1).

Fig. 1.

Clinical manifestations produced by herpes simplex viruses: the sites of infection by herpes simplex viruses include brain (meningitis, encephalitis), infections in the ocular area (eyes: keratitis, retinitis and conjunctivitis; mouth: lips and gingivostomatitis; facial nerves: facial paralysis), torso, limbs and genitals (neck, arms, hands, fingers, legs, genitals) and internal organs, such as lungs, kidneys and liver. The most frequent HSV serotype isolated for each pathology is indicated

Besides skin-related diseases, HSV are also associated with ocular complications, mainly epithelial or stromal keratitis (corneal infection with HSV) (Fig. 1). It is estimated that HSV is the first cause of blindness due to infection in the Western world [22, 23]. Although HSV-2 infects human corneal fibroblasts in vitro [24], as well as mouse corneas in the animal model [25], blindness by HSV in humans is generally attributed to HSV-1 [26–28]. Paradoxically, HSV infection of the retina (retinitis) is more frequently ascribed to HSV-2 in humans (Fig. 1) [29]. Similarly, acute necrotic retinitis is also frequently credited to HSV-2 [30, 31]. Other typical manifestations of HSV in the ocular area include eyelid infections and conjunctivitis (Fig. 1). These observations suggest that although both viruses share similarities in their capacity to infect cells derived from the ocular region, they may be isolated at slightly different frequencies depending on the disease produced.

A particularly relevant characteristic of HSV is that they also infect the central nervous system, which occurs more frequently in neonates than adults as a result of congenital infection from the mother to the newborn at the moment of birth. HSV infection of neonates can result in encephalitis and meningitis leading to severe neurological damage, such as mental retardation and to significant sequelae, as well as more dramatically death [32, 33]. This type of infection also occurs in adults, with HSV currently being the primary cause of viral encephalitis and meningitis worldwide [34, 35]. Although HSV-2 is capable of infecting the nervous system (0.016 % of cases), the main causative agent of encephalitis and meningitis in infants and adults is HSV-1 [35–37]. However, the number of cases of encephalitis and meningitis produced by HSV, as well as the specific virus producing these diseases, vary significantly between studies.

Another neurological illness associated with HSV is Mollaret’s syndrome (aseptic meningitis, recurrent benign leukocyte meningitis), in which one-third of the individuals suffer recurrent meningitis with spasm episodes, diplopia, pathological reflexes, cranial nerve paralysis, hallucinations and even coma (Fig. 1) [38–40]. This rare disease is characterized by aseptic inflammation of the meninges, which consists in leukocyte infiltration and the presence of Mollaret’s cells (giant mononuclear cells) in the inflamed tissue. Unlike encephalitis in adults, which is mainly produced by HSV-1, Mollaret’s syndrome is mainly attributed to HSV-2 [38, 39, 41]. Less clear is the participation of HSV in Bell’s palsy, a form of facial paralysis with unknown etiology (Fig. 1). Though HSV-1 is frequently referred as one of the causative agents of this disease [42, 43], other viruses, such as the human herpesvirus-6, have also been proposed to be involved in the onset of this form of facial paralysis [44, 45].

Although HSV infection is generally associated with skin, mucosal membrane and central nervous system pathologies, these viruses can also infect other tissues producing severe damage. Indeed, HSV infect a broad range of organs in the body, although in lower frequencies than the skin, mucosal membranes and eyes. Indeed, HSV can infect the liver [46, 47] and kidneys [47], and produce sepsis [46] (Fig. 1). These conditions rarely occur in immunocompetent individuals and usually predominate in immunocompromised and transplanted patients, as well as infants. Furthermore, HSV can also infect the lungs producing acute pulmonary damage (acute lung injury, ALI) and acute respiratory distress syndrome (ARDS) in both immunocompetent and immunocompromised individuals [47–49]. A recent study detected HSV-1 in 13 % of bronchoalveolar lavages obtained from patients with ALI/ARDS that were mainly intubated [50]. However, pulmonary infection with HSV is more frequently described in immunosuppressed individuals, such as those with advanced human immunodeficiency virus (HIV) infection, those undergoing chemotherapy and persons transplanted with solid organs or bone marrow [51–53].

Taken together, HSV produces a wide range of diseases in humans that can affect several organs. Although HSV-1 and HSV-2 may be isolated at different frequencies from the infected tissues, it is important to bear in mind that both viruses can produce similar diseases at these sites.

Incidence and prevalence of HSV-2

It is estimated that approximately 500 million people are currently infected with HSV-2 worldwide and that more than 20 million new cases arise each year [54]. The prevalence of HSV-2 varies significantly depending on the global region, ranging from ~5 % for countries such as Spain and up to 70 % for Sub-Saharan Africa [10, 54–56]. The United States currently displays a prevalence nearing ~16 %, which is below the global estimated average: 23.6 % [54, 57, 58]. For Europe, prevalence of HSV-2 varies significantly between countries ranging from ~5 % for England and Spain, ~20–30 % for countries such as Sweden, Denmark and Germany and up to 40 % for Turkey [56]. It is important to point out that the populations evaluated in these studies can vary significantly, as well as the methods used for determining seroprevalence (e.g., enzyme-linked immunosorbent assay vs. immunoblot) [56]. Remarkably, HSV-2 prevalence studies are rarely updated, and thus, prevalence values can significantly vary with time, as recently observed in a study that assessed pregnant women in Switzerland and reported prevalence values that jumped from 10 to 20 % in a 15-year period [59]. On the other hand, countries belonging to Asia and Oceania display prevalence rates ranging from ~5 % for New Zealand and Japan, ~10 % for Australia and the Philippines and up to ~20 % for China [56, 60]. For Latin America, there are relatively few epidemiological studies assessing the prevalence of HSV-2. One study suggests nearly 54 million cases for South America and the Caribbean [54]. A recent study in Peru determined that the prevalence of HSV-2 nears 15 % within 18- to 29-year-old individuals [61]. Brazil, on the other hand, displays a prevalence of HSV-2 close to 11 % [62], although certain studies suggest higher values [63, 64].

Noteworthy, the prevalence of HSV-2 infection is generally higher in women than in men with 50 % more cases occurring in the former group [54, 57, 65]. Although the reasons for these differences are unclear, it has been proposed that men might be more resistant to HSV-2 infection than women because of increased keratinization of the skin at the external surfaces of the genitalia.

Because HSV-2 infection is associated with susceptibility to HIV and increased shedding of the latter (see below), determining the prevalence of HSV-2 in the population is of public health relevance. Indeed, such epidemiological information could also help determine the effectiveness of sex education policies in different countries.

Although herpetic lesions at the oro-facial area (e.g., herpes labialis) are usually caused by HSV-1 and those occurring at the genitalia (herpes genitalis) are generally associated to HSV-2, HSV-1 is progressively emerging as the most common cause of primary genital herpes worldwide. Indeed, many studies have reported that HSV-1 may account for up to 80 % of cases of first-episode genital and anogenital herpes [12, 66–73]. Interestingly, a gradual transition from HSV-2 to HSV-1 as the leading causes of primary genital herpes can be observed in numerous recent studies [74–76]. Such a tendency would be explained in part by changes in the sexual behavior of the populations during the last decades [77]. On the other hand, up to 10 % of primary oro-facial herpes infections could be caused by HSV-2 [71]. However, this value may be underestimated because of infrequent serotypification or diagnosis of herpes labialis, which is shown in recent epidemiological studies [12]. Importantly, the capacity of both HSV-1 and HSV-2 to infect common tissues relies on the fact that the target receptors for these viruses are the same [78–80].

Because HSV-1 and HSV-2 remain latent in the host, variations in their reactivation/recurrence rates could significantly impact the frequencies at which each virus is isolated from a specific location in time. That is, increased incidence of a specific herpes simplex virus at a particular site might not necessarily relate to higher recurrences at that place in time, as this virus might recur there to a lesser extent than the other virus [81]. Indeed, despite the fact that HSV-1 is frequently isolated in primary genital infection, recurrences by this virus represent less than 10 % of the total cases of genital herpes [82, 83]. This apparent discrepancy would be explained by the low reactivation capacity of HSV-1 in the genital area, as compared to HSV-2 [81]. Effectively, it has been observed that HSV-1 reactivates significantly less in the genital area than HSV-2, the latter recurring 4–5 times a year, up to 6 times more than HSV-1 at this location [81, 84]. Inversely, it has been reported that HSV-2 recurs significantly less than HSV-1 at the oro-facial area [81]. Altogether, these findings provide a possible explanation for the different frequencies at which HSV-1 and HSV-2 are observed at specific anatomical sites during recurrences.

Infection with HSV does not always lead to symptoms or recurrences. However, 20–50 and 80–90 % of individuals that manifest primary symptomatic infections with HSV-1 and HSV-2, respectively, will develop genital recurrences during the first year of infection, while the remaining will rarely display any signs of disease [84]. Importantly, it has been observed that the frequency of future recurrences can be associated, at least in part with the severity of the primary infection episode [84]. On the other hand, the frequency and severity of recurrences by HSV tend to decreases in time, up to half the number of episodes over periods of 4 years [84]. The incidence of HSV-2 also varies greatly depending on the age of the individuals and is more pronounced once sexual activity is initiated. Currently, the highest infection rates in adults occur between ages 15 and 20 [54], although peak incidences at slightly higher ages are commonly observed in some populations [85].

The incidence of symptomatic neonate infection with HSV varies largely depending on the geographical region and time interval assessed. For instance, incidence rates in the United States have been shown to vary as much as from 1/25,000 to 1/1,500 live births when covering the years 1997 to 2010 [86–89]. Importantly, despite these low rates of detectable HSV infection at birth (symptomatic infection), prevalence of HSV-2 in children has been reported to be as high as 3–5 % and reach up to 15 % for some populations, such as children in urban regions of Tanzania [90, 91]. The significant differences between neonatal infection rates and prevalence of HSV infection in children could be due to unnoticed intrauterine or neonatal infection with HSV-2 [92], or non-sexual transmission of HSV by contaminated fingers and hands [13]. Noteworthy, mothers that are infected with HSV-2 recur more frequently as they progress through pregnancy, thus increasing the chances of virus transmission to the infant at the moment of birth [93]. These recurrences not necessarily need to be symptomatic to transmit infection, which complicates prevention of neonate infection [94, 95]. Nevertheless, the highest risk of infection to neonates occurs when mothers are undergoing primary infection and present severe HSV clinical manifestations [94, 96, 97]. Importantly, diagnosis of primary HSV infection at the time of delivery will require the analysis of both blood and swab samples for determining the type of infection [97].

Factors that modulate infection by HSV-2

Some factors that increase or decrease the probability of healthy individuals to acquire HSV-2 have been identified. One of these factors is the length of partner relationship, which correlates with the number of sexual intercourses. Indeed, it is estimated that 3.5 months of partner relationship or approximately 40 sexual intercourses are needed for an individual to be infected with HSV-2 by his/her partner [98]. This type of studies is possible thanks to the follow-up of discordant couples for HSV-2, which allow to identify risk factors associated with infection, as well as the probability of acquiring this virus [99]. The use of antivirals, such as valacyclovir (prodrug of acyclovir), has been shown to help decrease the probability of infection in this type of couples [100, 101]. Another factor that increases the probability of acquiring HSV-2 is evidently the number of sexual partners, which increases significantly the chances of encountering an HSV-2 infectious individual [102, 103]. On the other hand, factors that decrease the probability of infection with HSV-2 include the presence of natural antiviral molecules in the genital tissues. Indeed, infection with HSV-2 varies significantly between women depending on the presence of antiviral soluble compounds in the vagina that fluctuate with the hormonal cycle. For instance, human neutrophil peptides 1–3 (HNP1-3), interleukin 8 (IL-8), lactoferrin, lysozyme, immunoglobulin A (IgA) and IgG have been correlated with positive vaginal antiviral activities [104]. It is important to point out that individuals at the follicular phase present higher concentrations of these compounds as compared to individuals that use oral contraceptives, suggesting that the latter would be more vulnerable to infection with HSV-2 [104]. Consistent with this notion, some studies have associated the use of contraceptives with an increased risk of infection with HSV-2 and increased virus dissemination from the infected tissue [105, 106]. On the other hand, host molecules called defensins secreted in the genital tissue possess the capacity to block the infectivity of HSV-2. In vitro and in vivo experiments have demonstrated that human α-defensins (HD) HNP1-4, HD5 and HD6, as well as β-defensin 3 inhibit infection by HSV though the blockade of virus entry in target cells and during later processes [107]. Indeed, cervicovaginal washes of healthy patients contain these defensins and are able to reduce HSV-2 infection in vitro [108]. These results suggest that defensins present in cervicovaginal secretions play relevant roles in innate resistance to infection with HSV-2.

Aiming to evaluate possible differences between the susceptibility to HSV-2 infection between sexually active adolescent and adult women, some studies have quantified bacteria, such as Lactobacillus jensenii and Lactobacillus crispatus, in the genital tissue as biomarkers for mucosal immunity and to determine the relationship between these bacteria with susceptibility to infection by HSV-2. One of these studies suggests that adolescents posses significantly less activity against E. coli as compared to adult women, as well as reduced concentrations of total IgG and IgA which could account for lesser antimicrobial immunity [109]. However, adolescents presented significantly higher activities against HSV-2 in their vaginal secretions, as compared to adults and were more resistant to infection by this virus [109].

Taken together, we are just commencing to identify molecular factors that modulate infection at the genital tract, such as antimicrobial molecules present in this tissue, as well as their relationship with the infective capacity of pathogens. It is also important to consider the differential expression of these molecules in individuals of distinct ages for the design of future treatment strategies against vaginal infections.

Relationship between HSV-2 and HIV

An important finding in the last decades is the fact that infection with HSV-2 increases 3–4 times the likelihood of acquiring HIV, thus significantly contributing to the epidemics of acquired immunodeficiency syndrome (AIDS) [110–112]. Moreover, it has been evidenced that HSV-2 significantly increases the dissemination of HIV in the genitalia of those co-infected with these viruses [113]. It is important to note that the relationship between HIV and HSV-2 is reciprocal, as infection with HIV also significantly increases the probability of acquiring HSV-2, and that reactivation with HSV-2 is more frequent in HIV-positive patients [114–116]. Noteworthy, the relationship between HSV-2 and HIV is synergic and goes beyond risk factors associated with the acquisition of these viruses.

The molecular mechanisms that relate HSV-2 and HIV are just beginning to be elucidated. One of the mechanisms by which infection with HSV-2 increases the probability of acquiring HIV is through the generation of microlesions by HSV-2 at the site of infection, which exposes immune cells in the epidermis and dermis to HIV (Fig. 2). Effectively, immune cells such as dendritic cells (DCs), Langerhans cells and macrophages reside these zones and patrol the tissues to detect microbes (Fig. 2) [117]. These cells are important targets for HSV-2 and HIV [118, 119]. On the other hand, a recent study found that the foreskin of individuals infected with HSV-2 contained significantly higher number of CD4⁺ T cells than foreskins from non-infected individuals, thus increasing the probability that HIV encounters these target cells at this site (Fig. 2) [120]. Another clinical study found that vaginal infection with HSV-2 significantly increased the number of DCs (up to tenfold) and CD4⁺ T cells (threefold) at the site of infection, and that these cells expressed DC-SIGN and CCR5, respectively, both receptors for HIV (Fig. 2) [121]. Furthermore, it has been found that macrophages infected with HSV-2 increased their expression of CCR5 at their surface, rendering them more susceptible to HIV infection [122]. Finally, infection of Langerhans cells with HSV-2 reduced the expression of langerin in these cells, a molecule that mediates the capture and degradation of HIV [123]. These effects promote DC infection with HIV and consequent transfer of this virus to T cells in the tissue and lymph nodes (Fig. 2). Moreover, infection of dendritic cells with HSV-2 significantly increases the expression of integrin α₄β₇ at the surface of CD4⁺ T cells, which makes these cells more susceptible to HIV infection (Fig. 2) [119]. Taken together, infection with HSV-2 promotes the recruitment of immune cells at the site of infection that are targets for HIV, thus increasing the chances that these cells be successfully infected by the latter virus (Fig. 2).

Fig. 2.

Relationship between HSV-2 and HIV at the site of infection. Infection with HSV-2 produces microlesions that expose the epidermis, dermis and subjacent immune cells at the site of infection to incoming viruses, such as HIV. 1. Infection of genital epithelia by HSV-2 produces the secretion of pro-inflammatory cytokines (e.g., IL-6, TNF-α, IL-1β, RANTES) in response to infection, which attracts immune cells, such as dendritic cells and T cells to the site of infection. 2. Residing and infiltrating immune cells (DCs and T cells) are infection targets for HSV-2 and HIV. 3. DC infection with HSV-2 induces the secretion of soluble molecules at the site of infection that promote the reactivation of HIV from CD4⁺ T cells in HIV⁺ individuals with subsequent replication and dissemination. 4. DCs infected with HSV-2 recruit T cells that express α₄β₇, a molecule that facilitates infection of these cells by HIV. 5. DCs accumulating at the site of infection can be used by HIV as Trojan horses to reach and infect T cells in lymph nodes

On the other hand, it has been recently demonstrated that human dendritic cells infected with HSV-2 secrete cytokines that promote the reactivation of HIV from cells latently infected with this retrovirus (Fig. 2) [118]. Although this last observation does not directly relate to the probability of acquiring HIV, these results suggest that HIV⁺/HSV-2⁻ individuals would display increased progression to AIDS after infection with HSV-2, as well as they would manifest increased probabilities of infecting their sexual partners with HIV.

Thanks to the implementation of a murine model that recapitulates the higher susceptibility to acquire HIV after HSV-2 infection, new molecular mechanisms that relate both viruses will likely be identified in the near future [124].

Another aspect relating HIV infection with increased transmission of HSV-2 is combination antiretroviral therapy (cART). Some studies have shown that suppressive antiretroviral therapy in HIV-positive patients can significantly increase genital ulcer disease (GUD) because of HSV-2 reactivation [125], although some have not observed this phenomenon [126]. Nevertheless, patients receiving cART therapy together with the antiviral acyclovir generally display significantly less GUD and HSV-2 shedding than those receiving cART alone, and thus, HIV⁺/HSV⁺ individuals are frequently prescribed with acyclovir [125, 127–129]. However, the chronic use of acyclovir in these patients has been shown to promote the emergence of HSV isolates that are resistant to this drug. Indeed, acyclovir-resistant HSV can be isolated in 3.5–10 % of immunocompromised patients receiving this antiviral [127–129] compared to <1 % of immunocompetent individuals [127, 129, 130]. HSV-resistance to acyclovir mainly results as a consequence of point mutations in the viral thymidine kinase (TK, UL23) and the viral DNA polymerase (DNA pol, UL30) (Table 1) [131–136].

Table 1.

Mutations identified in acyclovir- and foscarnet-resistant HSV-2 isolates

Phenotypic susceptibility/resistance		Viral TK mutations	Viral DNA polymerase mutations	References
Acyclovir	Foscarnet
>2 μg/ml	>100 μg/ml	G59P; a,bM183Stop; a,bD229Stop; a,bL263Stop.	c A724T; c S729N; c L783M; d D785N; c L850I; e D912V.	Schmit and Boivin [135]
>10 μg/ml	<200 μg/ml	R34C; f[P85S; N100H; V192M]; a,bM86Stop; R177W; Y239Stop; a,bM348Stop.	gE250Q; gR628C; gE678G; gD912N.	Chibo et al. [131]
>8.9 μM	–	f[G25A; Y53N; R221H]; hG39E; f[R86P; bL263Stop]; Y133F.	No mutations identified.	Sauerbrei et al. [132]
>7 μM	<330 μM	gS29A; f[G39E; N78D; M70R]; f[S66P; A72S]; bD137Stop; bT184Stop; R221H; bQ222Stop.	d D785N.	Burrel et al. [133]
>7 μM	–	S66P; A72S; I101S; M183I.	Not assessed.	Burrel et al. [136]
>7 μM	>330 μM	iG61W; bM86Stop; iA94V; bL98Stop; iS169P; G201D; iR221C; T288M; Del aa 1-248.	iD307N; i K592E; i Q732R; iQ829R; i T844I; iA915V.	Burrel et al. [134]

Mutations within HSV-2 TK and DNA polymerase that confer resistance to ACV/FOS

^aStop codon positions were inferred from nucleotide deletions/insertions reported within UL23 using HSV-2(HG52) as a reference sequence (NCBI Reference Sequence: NC_001798.1)

^bStop codons mainly occur as a result of frameshifts caused by different nucleotide insertions or deletions at different positions within the UL23 gene. Stop codons identified in more than one study in the table are only indicated once in the earliest report

^cMutations associated with resistance to foscarnet are indicated in bold

^dMutation conferring reduced susceptibility to foscarnet

^eMutation identified in an acyclovir/foscarnet-resistant isolate also encoding the acyclovir-resistance M183Stop mutation

^fSet of mutations identified in single acyclovir-resistant viral isolates

^gMutations identified within the DNA pol of acyclovir-resistant/foscarnet-sensitive viral isolates

^hMutation with unclear significance. This mutation does not reduce the phosphorylation activity of TK [136]

ⁱMutations indicated as potentially involved in resistance to acyclovir and/or foscarnet

Importantly, viral strains with point mutations in the viral TK or DNA pol genes display reduced neurovirulence in animal models, and loss of viral TK activity dramatically impairs virus reactivation from latency [137–139]. Because of the reduced virulence of acyclovir-resistant isolates, these viruses are detected nearly ten times less in healthy individuals than those that are immunocompromised [138, 140]. Nevertheless, viral strains presenting impaired TK activity can produce significant disease in neonates, such as encephalitis [141, 142].

A drug frequently used to combat acyclovir-resistant HSV strains in AIDS patients and bone marrow transplanted individuals is foscarnet (phosphonoformic acid, PFA) [143, 144]. This compound is a pyrophosphate analogue that inhibits the viral DNA polymerase by mimicking the structure of pyrophosphate recruited during the elongation of HSV DNA [145]. Although foscarnet-resistant HSV strains are rarely isolated (Table 1) [135, 146–148], unfortunately this drug displays some renal toxicity and requires administration under medical supervision. Other alternatives against acyclovir-resistant HSV isolates include cidofovir (which also affects the kidneys) and imiquimod, which is emerging as an attractive alternative to common antiviral drugs [149, 150].

Therapeutic and prophylactic antivirals and microbicides

Therapeutic and prophylactic antivirals

Antivirals such as acyclovir have been used since long to treat infections with HSV and other herpesviruses. The efficacy of this drug is significant when applied early after infection; however, it does not clear viral latency or alter the frequency of recurrences after acute treatment. Acyclovir is a guanosine nucleoside analog that once internalized into infected cells is processed into a monophosphorylated form that is subsequently phosphorylated into acyclovir triphosphate by host kinases [151]. In this form, acyclovir triphosphate inhibits viral replication by interfering with the activity of the viral polymerase [151, 152]. Because of its antiviral properties, acyclovir and its prodrug valacyclovir have also been assessed as therapeutic and prophylactic drugs for decreasing the transmission of HSV-2 onto sexual partners. Although valacyclovir has been shown to help decrease the transmission of HSV-2 from HSV-2⁺/HIV⁻ individuals onto their couples [100, 101], acyclovir has been shown ineffective to do so for partners of HSV-2⁺/HIV⁺ co-infected individuals (Table 2) [153].

Table 2.

Therapeutic and prophylactic antivirals and microbicides against HSV-2

Compound	Chemical composition	Mechanism	Study stage	Findings
Therapeutic and prophylactic antivirals
Tenofovir	Nucleotide analog	Interferes with viral replication	Clinical phase 1	Inhibits up to 51 % the transmission of HSV-2
Acyclovir	Guanosine nucleotide analog	Interferes with viral replication	Clinical phase 2	Does not decrease the risk of HSV-2 transmission
TDF	Tenofovir disoproxil fumarate, pro-drug of tenofovir, nucleotide analog	Interferes with viral replication	in vivo in animals	Intravaginal devices have been designed for its continuous administration. Protects against HSV-2 in animals
Microbicides/antivirals tested in clinical settings
Nonoxinol-9 (N-9)	Organic surfactant with 9 etoxide group repetitions	Interferes with the virion membrane	Clinical phase 1	Increased risk of acquiring HIV
SPL7013, VivaGel®	Dendrimer. Nucleus: Benzhydrilamine. Ramifications: lysine. Tips: naphthalene disulfonic acid	Inhibits the adhesion and entry of HIV and HSV-2 into target cells	Clinical phase 1	Protects against HSV-2. Does not display usage complications
Cellulose sulfate	Cellulose sulfate	Emulates heparan sulfate receptor, binds viral gB	Clinical phase 2	No protection against HIV or HSV-2. Increases the risk of acquiring HIV
C31G	Ionic surfactant	Interferes with the virion membrane	Clinical phase 3	Adverse effects in the genital tissue. Increases the susceptibility to HIV and HSV-2
PRO 2000	Naphthalene sulfonic acid	Emulates heparan sulfate receptor, binds viral gB	Clinical phase 3	No protection against HIV and HSV-2
Microbicides/antivirals currently being evaluated in vitro and in vivo
Labyrinthopeptin A1	Carbacyclic lantibiotic	Unknown	In vitro	anti-HSV-2 and HIV activity. Synergism with acyclovir and tenofovir
PD 404,182	6H-6-Imino-(2,3,4,5-tetrahidropirimido)[1,2-c]- [1,3] benzothiazine	Interrupts the viral membrane, release of viral content	In vitro	Non-toxic. Has anti-HSV-2 and HIV activity
Zinc acetate and carrageenin	Zinc acetate and carrageenin	Binding of Zn to viral membrane glycoproteins. Blocks HSV-2 entry	In vivo	Poor reduction of HSV-2 infection in animals
Meliacine	Melia azedarach leaf extract	Unknown	In vivo	Reduces HSV-2 disease symptoms and the release of virus in animals
MI-S	Agaricus brasilensis sulfated polysaccharide	Impairs the entry of virus into cells	In vivo	Reduces HSV-2 disease symptoms and lethality in animals
Griffithsin	Homo-dimeric lectin	Blocks cell-to-cell virus dissemination	In vivo	Prevents virus dissemination and disease in animals

On the other hand, an antiviral that has acquired important attention, mainly because of its anti-HIV activity is tenofovir (TFV) and the oral pro-drug tenofovir disoproxil fumarate (TDF) [154]. Clinical studies in humans orientated to determinate the efficacy of TFV against HIV have demonstrated that this drug also possesses anti-HSV-2 effects, reducing the transmission of this virus up to 51 % [155]. Consistent with this observation, in vitro and in vivo studies in the murine model and macaques have demonstrated that TFV and TDF both possess antiviral capacity against HSV-2 (Table 2) [156–158]. However, one study determined that TDF would not affect the dissemination of HIV and HSV-2 in individuals co-infected with both viruses [159].

One of the major challenges of using antivirals is adherence. It is estimated that negative results recently obtained in a clinical study with TFV would mainly be due to this problem [160]. Thus, novel strategies seek to deliver these dugs in a continuous way using synthetic intravaginal rings (IVRs) that could be introduced into the vaginal cavity to release TDF in a steady fashion. To date, IVRs have been miniaturized with the aim to assess their efficacy in assays with vaginal tissue explants and double-chamber models with polarized epithelial cells, in which it has been observed that this strategy significantly reduces the infective capacity of HIV and HSV-2 [161]. More recently, IVRs that release TDF have also been tested, with promising results in non-human primates to prevent infection with HIV [157]. Effectively, macaques that received IVRs with TDF and were challenged with virus continuously for 16 weeks remained seronegative for SIVH (an HIV chimera for simians) (Table 2) [157]. It is expected that similar experiments will be performed in the short term to assess the protective capacity of these IVRs against HSV-2.

Microbicides/antivirals assessed in clinical settings

Because of the important association between HSV-2 and HIV, as well as the recurrence of genital lesions produced by infection with HSV, the identification of novel prophylactic drugs against these viruses is of high interest for public health systems worldwide. Although vaccines usually present better cost-effectiveness ratios than drugs, the absence of prophylactic alternatives against HSV-2 has promoted the search for new microbicides/antivirals that could help combat infection or clinical manifestations produced by this virus. A compound with anti-HSV-2 activity in vitro is the spermicide Nonoxynol-9 (N-9), which has been used for more than 30 year as a contraceptive (Table 2) [162]. N-9 also possess anti-HIV activity in vitro [163]. However, when assessed in clinical assays, it was found that repetitive applications of N-9 significantly increased the probability of acquiring vaginal infection with HIV [164] and papilloma virus (VPH) [165]. Furthermore, the application of N-9 in animal models has shown to significantly increase their susceptibility to infection with HSV-2 [166, 167]. Thus, the recommendation to use N-9 as a microbicide is being discontinued in individuals at risk of contracting sexually transmitted infections. These negative effects of N-9 would be due in part to the toxicity of this compound to the genital tissue, as evidenced in animals [168]. Furthermore, N-9 would interrupt the junctions between epithelial cells, characterized by the loss of adhesion and tight junction proteins, thus allowing the entry of viral particles to a broader range of target cells in the genital tract [167].

Another compound with microbicide potential is SPL7013, better known as VivaGel^® (Table 2) [169]. This compound has been demonstrated to significantly inhibit the entry of HIV and HSV into human cells obtained from biopsies [170]. A clinical study evaluated the security, adherence and effect of VivaGel^® on the microbiome of the vagina of women sexually active and found that, although this compound modified the microbiome, this did not translate into serious complications for the individuals [170]. Because of these favorable results, it is expected that this microbicide will soon be evaluated in more advanced clinical trials in humans. Other microbicides with anti-HSV-2 and anti-HIV activity in vitro include the surfactants SDS and C31G (Savvy), which act by interrupting the membrane and proteins of these viruses (Table 2) [171, 172]. Nevertheless, as for N-9, these compounds have demonstrated some toxicity in the vaginal tissue in animal models, as well as increased susceptibility to infection with HSV-2 [168]. Furthermore, in a phase I clinical trial, C31G produced adverse effects, such as vulvovaginitis, and thus, its use as a microbicide has been discontinued [173].

Cellulose sulfate [174] and PRO 2000 [175] are two molecules that emulate sulfate heparan and display an important capacity to block the entry of HSV-2 into target cells (Table 2). Although in vitro studies suggest that these molecules bind to the viral surface glycoprotein gB, which is essential for virus infection [176], clinical assays with these drugs demonstrated that PRO 2000 and cellulose sulfate would not confer significant protection against HSV-2 or HIV, and even associated the use of cellulose sulfate with an increase in contracting HIV (Table 2) [177, 178].

Noteworthy, studies aiming at identifying effective compounds against HSV have found that the seminal plasma can significantly reduce the effectiveness of microbicides, such as PRO 2000 and cellulose sulfate [179]. To obtain activities similar to those observed in the absence of seminal plasma, in some cases, it was necessary to increase the concentration of the drugs tested up to 100-fold [179]. Importantly, it has been observed that the seminal plasma can inhibit the binding of microbicides to the envelope of HSV-2 [179]. The main proteins identified to mediate this inhibition were fibronectin-1 and lactoferrin [179]. Thus, when assessing the effectiveness of microbicides, it will be important to consider the negative activity of seminal plasma over the activity of these compounds.

Microbicides/antivirals currently being evaluated in vitro and in vivo

Because microbicides have emerged as an attractive strategy to combat HSV, numerous compounds are currently being evaluated in vitro and in vivo for determining their anti-HSV properties. Two of these compounds are labyrinthopeptin A1 and PD 404,182 (Table 2). Labyrinthopeptin A1 is a carbacyclic lantibiotic with potent activity against HIV and HSV in vitro, capable of acting synergistically with acyclovir and tenofovir, within others [180]. PD 404,182, on the other hand, is capable of affecting the integrity of HIV and HSV through its interaction with viral protein components [181]. This latter compound has been demonstrated to be innocuous for the vaginal tissue and its microflora, as well as preserve its pH in the presence of seminal plasma.

Another microbicide with potential is the combination of zinc acetate and carrageenin (AZ/CG) (Table 2) [182]. AZ/CG decreases up to 80 % infection with HSV-2 in macaques, and its activity would be mediated by the binding of Zn to viral membrane glycoproteins impairing the entry of the virus into target cells [183]. Nevertheless, upon intravaginal challenge with HIV and HSV-2, the effectiveness of AZ/CG against HSV-2 was dramatically reduced up to 20 %, while protection against HIV was maintained [184].

Finally, some microbicides/antivirals derived from natural compounds with anti-HSV-2 activity have been characterized and tested in animal models, such as Meliacine and MI-S (Table 2). Meliacine is a derivative extracted from Melia azedarach and has demonstrated favorable results in mice against HSV-2 after topic application immediately after challenge with this virus [185]. MI-S, on the other hand, is a sulfated compound of a polysaccharide of the fungus Agaricus brasilensis, which has been observed to act over the binding of the virus and its entry into host cells; this compound reduced the clinical severity of the disease produced by HSV, as well as mortality in the murine model after one single application 20 min before infection (Table 2) [186]. Finally, the homo-dimeric lectin griffithsin extracted from the red algae Griffithsia sp., binds manose N-glycosilations in gp120 from HIV to block its binding to its receptor (Table 2) [187]. Additionally, griffithsin has been shown in the murine model of HSV-2 infection to reduce infection with this virus, as well as pathology by blocking cell-to-cell spread in the infected tissue [188]. These compounds should now progress into macaques and then humans.

The assessment of microbicides as an alternative against HSV-2 has experimented a significant increase in the field of prophylactics against this virus with some promising results that should translate into clinical studies. Noteworthy, the majority of the microbicides against HSV-2 assessed until now also share activity against HIV and vice versa. This finding suggests similar properties between both viruses as well as a somewhat lack of specificity for these types of antimicrobial agents. Important challenges for future microbicides/antivirals include granting constant administration of their active principles, reducing their toxic effects over the genital tissues and identifying early on detrimental effects, such as increasing infection with other pathogens. It is also important to consider the effectiveness of these compounds under variations of the hormonal cycle of individuals, age and presence of seminal plasma.

Concluding remarks

Although herpes simplex viruses were identified and isolated early in human history, to date, there is no treatment available to cure infection or vaccine to prevent their acquisition. The lack of successful treatment alternatives and vaccines against herpes simplex viruses has not only been troubled by effective molecular mechanisms evolved by these pathogens, but also likely by their somewhat unrecognized impact in public health until recently. Indeed, the currently identified relationship between HSV-2 and HIV calls for significant attention at controlling HSV-2 infection, which is highly prevalent worldwide. In this regard and in spite of the lack any vaccine against HSV, microbicides have emerged as promising alternatives that could reach the population fast enough to slow down HSV-2 spread. Recent favorable results in animal models should translate shortly into new clinical trials in humans that will seek to limit the impact of HSV-2 infection on the HIV epidemics.